TYK2/JTK1
TYK2 (tyrosine kinase 2, also called JTK1) is the fourth Janus kinase, discovered as the first kinase partner of the interferon-alpha/beta receptor and now known to pair with receptors for type I interferons, interleukin-12 and -23, and IL-10-family cytokines. Through STAT1, STAT2, STAT3 and STAT4, TYK2 shapes antiviral immunity, T-helper-1 differentiation and inflammatory interleukin-17 responses. Genome-wide association studies repeatedly link TYK2 variants to autoimmune diseases including psoriasis, lupus and inflammatory bowel disease. Unlike other JAK inhibitors that bind the active site, the allosteric TYK2 inhibitor deucravacitinib targets the pseudokinase (JH2) domain and is approved for moderate-to-severe plaque psoriasis, validating pseudokinase-directed pharmacology and TYK2's central role in inflammatory skin disease.
-
TYK2/JTK1 Recombinant Proteins (3)
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
Recombinant Protein Expression Service
- Codon Optimization
- Gene Synthesis
- Construction of Expression Vector
- Strain Screening
- Protein Expression
- Purification & QC
- Protein Delivery
- Formula: Human
- Molecular Weight: Sf9 insect cells
The EpCAM/TROP1 protein serves as an important homogeneous interacting molecule that promotes direct contact between intestinal epithelial cells (IEC) and intraepithelial lymphocytes (IEL) in the mucosal epithelium. This feature helps establish an immune barrier against mucosal infections. EpCAM/TROP1 Protein, Human (His-SUMO) is the recombinant human-derived EpCAM/TROP1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.
